Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

BestTreat · BestTreat – Building a Gut Microbiome Engineering Toolbox for In-Situ Therapeutic Treatments for Non-alcoholic Fatty Liver Disease

H2020Status: CLOSED1 September 201831 August 2022EU funding €4,134,156Call H2020-MSCA-ITN-2018

BestTreat fosters education of ESRs in a project to uncover microbiome signatures for risk prediction and monitoring of NAFLD and to contribute to the development of therapeutic treatments based on metabolically beneficial microbial consortia. It trains 15 ESRs at world-leading academic institutions and companies, thus forming strong interdisciplinary links between industry, life and medical sciences, and end-users. BestTreat aims to train a new generation of highly qualified ESRs with entrepreneurial competencies in modern Life Sciences through state-of-the-art research projects. The projects focus on the identification and functional characterization of microbial consortia that contribute to metabolic control, and the application of this knowledge to develop novel leads for drug discovery and therapies for NAFLD. The new field on microbiome based therapeutics requires highly skilled scientists with interdisciplinary knowledge on medicine, systems biology and computer science, as well as hands-on experience with several types of tissue samples and model organisms that can optimally translate their research findings into sustainable improvements in clinical practice. BestTreat overcomes current barriers by establishing a strong, multidisciplinary and inter-sectoral training network, developing technologies tailored to solve key questions in human metabolism, microbiology and bioinformatics. The BestTreat programme will exploit recent developments in high-throughput and genome-wide screening technologies, combine these with modern molecular cell biology and systems biology approaches and ultimately translate the data into new leads for the discovery of live biotherapeutics. This specific cross-disciplinary training program will educate young scientists to the next level needed to advance this research field for the upcoming decennium. The training programme will be complemented with a complete set of transferable skills.

Consortium · 14 organisations

coordinator

LEIBNIZ-INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE EV HANS-KNOLL-INSTITUT

DE · €758,365

participant

RIJKSUNIVERSITEIT GRONINGEN

NL · €531,240

partner

GUBRA APS

DK

partner

BIOFACTION KG

AT

partner

BRAVAD PRODUCTION APS

DK

participant

AFEKTA TECHNOLOGIES LTD

FI · €280,806

partner

FRIEDRICH-SCHILLER-UNIVERSITÄT JENA

DE

partner

UDATHA DASARADHI

SE

participant

DANMARKS TEKNISKE UNIVERSITET

DK · €595,044

participant

CHR. HANSEN AS

DK · €297,522

participant

CLINICAL-MICROBIOMICS AS

DK · €297,522

partner

SHANGHAI SIXTH PEOPLE'S HOSPITAL

CN

participant

ITA-SUOMEN YLIOPISTO

FI · €842,417

participant

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

NL · €531,240

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.